× Information on this section of ECOLEX comes from the InforMEA Portal which compiled information from MEA Secretariats with the support of the European Union. The accuracy of the information displayed is the responsibility of the originating data source. In case of discrepancy the information as displayed on the respective MEA website prevails. Decision XVII/5: Essential-use nominations for Parties not operating under paragraph 1 of Article 5 for controlled substances for 2006 and 2007 Document type Decision Reference number XVII/5 Date Dec 16, 2005 SourceUNEP, InforMEA Status Active Subject Waste & hazardous substances, Air & atmosphere Treaty Montreal Protocol on Substances that Deplete the Ozone Layer (Sep 16, 1987) Meeting Seventeenth Meeting of the Parties Website ozone.unep.org Abstract Noting with appreciation the work done by the Technology and Economic Assessment Panel and its Medical Technical Options Committee, Noting with appreciation the progress made since the adoption of decision XV/5 by Parties not operating under paragraph 1 of Article 5 of the Montreal Protocol in establishing a certain date by which they will cease submitting nominations for metered-dose inhalers where the sole active ingredient is salbutamol, Recalling paragraph 6 of decision XV/5 relating to the phase-out of chlorofluorocarbons for metered-dose inhalers where the active ingredient is not solely salbutamol, To authorize the levels of production and consumption for 2006 and 2007 necessary to satisfy essential uses of chlorofluorocarbons for metered-dose inhalers for asthma and chronic obstructive pulmonary disease as specified in the annex to the present decision; That Parties not operating under paragraph 1 of Article 5 of the Montreal Protocol, when licensing, authorizing, or allocating essential-use exemptions for chlorofluorocarbons for a manufacturer, shall take into account pre- and post-1996 stocks of controlled substances as described in paragraph 1 (b) of decision IV/25, such that no more than a one‑year operational supply is maintained by that manufacturer; With reference to paragraph 6 of decision XV/5, to request that Parties not operating under paragraph 1 of Article 5 of the Montreal Protocol submit a date to the Ozone Secretariat prior to the Eighteenth Meeting of the Parties by which time a regulation or regulations to determine the non‑essentiality of the vast majority of chlorofluorocarbons for metered-dose inhalers where the active ingredient is not solely salbutamol will have been proposed; Annex Essential-use nominations for 2006 and 2007 of chlorofluorocarbons for metered-dose inhalers approved by the Seventeenth Meeting of the Parties (metric tonnes) 2006 2007 Party Amount nominated Amount approved Amount nominated Amount approved European Community 539 539 - - Russian Federation 400 400 243 243 United States of America 1702 1100 1493 1000